<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36882195</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>American journal of hematology</Title><ISOAbbreviation>Am J Hematol</ISOAbbreviation></Journal><ArticleTitle>Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia.</ArticleTitle><Pagination><StartPage>857</StartPage><EndPage>868</EndPage><MedlinePgn>857-868</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.26900</ELocationID><Abstract><AbstractText>Pediatric chronic immune thrombocytopenia (cITP) is a heterogeneous condition in terms of bleeding severity, second-line treatment use, association with clinical and/or biological immunopathological manifestations (IMs), and progression to systemic lupus erythematosus (SLE). No risk factors for these outcomes are known. Specifically, whether age at ITP diagnosis, sex, or IMs impact cITP outcomes is unknown. We report the outcomes of patients with pediatric cITP from the French nationwide prospective cohort OBS'CEREVANCE. We used multivariate analyses to investigate the effect of age at ITP diagnosis, sex, and IMs on cITP outcomes. We included 886 patients with a median (min-max) follow-up duration of 5.3 (1.0-29.3) years. We identified an age cutoff that dichotomized the risk of the outcomes and defined two risk groups: patients with ITP diagnosed &lt;10&#x2009;years (children) and &#x2265;&#x2009;10&#x2009;years (adolescents). Adolescents had a two to four-fold higher risk of grade &#x2265;3 bleeding, second-line treatment use, clinical and biological IMs, and SLE diagnosis. Moreover, female sex and biological IMs were independently associated with higher risks of biological IMs and SLE diagnosis, second-line treatment use, and SLE diagnosis, respectively. The combination of these three risk factors defined outcome-specific risk groups. Finally, we showed that patients clustered in mild and severe phenotypes, more frequent in children and adolescents, respectively. In conclusion, we identified that age at ITP diagnosis, sex, and biological IMs impacted the long-term outcomes of pediatric cITP. We defined risk groups for each outcome, which will help clinical management and further studies.</AbstractText><CopyrightInformation>&#xa9; 2023 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pincez</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9412-333X</Identifier><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence National des Cytop&#xe9;nies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Department of Pediatrics, Sainte-Justine University Hospital, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Helder</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence National des Cytop&#xe9;nies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hemato-Immunology, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquet</LastName><ForeName>Marl&#xe8;ne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Immunology Hematology Unit, Children's University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou Chahla</LastName><ForeName>Wadih</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granel</LastName><ForeName>J&#xe9;rome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence National des Cytop&#xe9;nies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hemato-Immunology, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;ritier</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0384-6370</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, AP-HP, Armand Trousseau University Hospital, Pediatric Hematology Oncology Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahd</LastName><ForeName>Mony</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Hematology Unit, Robert-Debr&#xe9; University Hospital AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducassou</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7736-0838</Identifier><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence National des Cytop&#xe9;nies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hemato-Immunology, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Hematology Unit, Nantes University Hospital, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garnier</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barlogis</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology, La Timone Hospital, Marseille University Hospital, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeziorski</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Hematology Unit, Arnaud de Villeneuve University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayart</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatric Hematology Unit, Rennes University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chastagner</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, Children's University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheikh</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology-Oncology, Besan&#xe7;on University Hospital, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guitton</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Bic&#xea;tre University Hospital, AP-HP, Le Kremlin-Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paillard</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, Hautepierre University Hospital, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lejeune</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology-Oncology, Clocheville Hospital, Tours University Hospital, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millot</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology, Poitiers University Hospital, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li-Thiao Te</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology/Oncology, Amiens University Hospital, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallebranche</LastName><ForeName>Coralie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Unit, Angers University Hospital, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pediatric Unit, Angers University Hospital, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neven</LastName><ForeName>B&#xe9;n&#xe9;dicte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pediatric Hematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armari-Alla</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Hematology-Oncology Department, Grenoble University Hospital, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carausu</LastName><ForeName>Liana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology, CHU de Brest, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piguet</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Hematology Unit, Limoges University Hospital, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benadiba</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology-Oncology Pediatrics, Nice University Hospital, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pluchart</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Hematology-Oncology Unit, Institut Jean Godinot, Reims University Hospital, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, North Hospital, University Hospital of Saint Etienne, Saint Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deparis</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Oncology- Hematology Unit Department, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briandet</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dor&#xe9;</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatric Unit, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie-Cardine</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblanc</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pediatric Hematology Unit, Robert-Debr&#xe9; University Hospital AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverger</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, AP-HP, Armand Trousseau University Hospital, Pediatric Hematology Oncology Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aladjidi</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence National des Cytop&#xe9;nies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hemato-Immunology, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hematol</MedlineTA><NlmUniqueID>7610369</NlmUniqueID><ISSNLinking>0361-8609</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36882195</ArticleId><ArticleId IdType="doi">10.1002/ajh.26900</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.</Citation></Reference><Reference><Citation>Schifferli A, Holbro A, Chitlur M, et al. A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. Am J Hematol. 2018;93(6):751-759.</Citation></Reference><Reference><Citation>Heitink-Poll&#xe9; KMJ, Nijsten J, Boonacker CWB, de Haas M, Bruin MCA. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295-3307.</Citation></Reference><Reference><Citation>Edslev PW, Rosth&#xf8;j S, Treutiger I, et al. A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic trombocytopenic purpura in children. Br J Haematol. 2007;138(4):513-516.</Citation></Reference><Reference><Citation>Revel-Vilk S, Yacobovich J, Frank S, et al. Age and duration of bleeding symptoms at diagnosis best predict resolution of childhood immune thrombocytopenia at 3, 6, and 12 months. J Pediatr. 2013;163(5):1335-1339.e2.</Citation></Reference><Reference><Citation>Neunert CE, Buchanan GR, Imbach P, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the intercontinental cooperative ITP study group (ICIS). Blood. 2013;121(22):4457-4462.</Citation></Reference><Reference><Citation>Flores A, Klaassen RJ, Buchanan GR, Neunert CE. Patterns and influences in health-related quality of life in children with immune thrombocytopenia: a study from the Dallas ITP cohort. Pediatr Blood Cancer. 2017;64(8):e26405.</Citation></Reference><Reference><Citation>Grace RF, Klaassen RJ, Shimano KA, et al. Fatigue in children and adolescents with immune thrombocytopenia. Br J Haematol. 2020;191(1):98-106.</Citation></Reference><Reference><Citation>Ducassou S, Gourdonneau A, Fernandes H, et al. Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25&#x2009;years. Br J Haematol. 2020;189(5):931-942.</Citation></Reference><Reference><Citation>Rosth&#xf8;j S, Rajantie J, Treutiger I, et al. Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort. Acta Paediatr. 2012;101(7):761-766.</Citation></Reference><Reference><Citation>Bansal D, Bhamare TA, Trehan A, Ahluwalia J, Varma N, Marwaha RK. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer. 2010;54(3):403-407.</Citation></Reference><Reference><Citation>Hadjadj J, Aladjidi N, Fernandes H, et al. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood. 2019;134(1):9-21.</Citation></Reference><Reference><Citation>Pincez T, Fernandes H, Leblanc T, et al. Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden. Haematologica. 2022;107(2):457-466.</Citation></Reference><Reference><Citation>Grace RF, Lambert MP. An update on pediatric immune thrombocytopenia (ITP): differentiating primary ITP, IPD, and PID. Blood. 2022;140(6):542-555.</Citation></Reference><Reference><Citation>Saettini F, Cattoni A, Redaelli M, et al. Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. Acta Paediatr. 2021;110(2):643-651.</Citation></Reference><Reference><Citation>Hazzan R, Mukamel M, Yacobovich J, Yaniv I, Tamary H. Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 2006;47(S5):657-659.</Citation></Reference><Reference><Citation>Pincez T, Aladjidi N, Heritier S, et al. Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. Blood. 2022;140(3):253-261.</Citation></Reference><Reference><Citation>Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141(5):683-688.</Citation></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.</Citation></Reference><Reference><Citation>Bousfiha A, Moundir A, Tangye SG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508-1520.</Citation></Reference><Reference><Citation>Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH international workshop. Blood. 2010;116(14):e35-e40.</Citation></Reference><Reference><Citation>World Health Organization. Adolescent health. 2022 https://www.who.int/health-topics/adolescent-health</Citation></Reference><Reference><Citation>Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the intercontinental cooperative ITP study group registry II participants. Pediatr Blood Cancer. 2018;65(1):e26736.</Citation></Reference><Reference><Citation>Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum. 2012;64(7):2356-2365.</Citation></Reference><Reference><Citation>Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118(18):4798-4807.</Citation></Reference><Reference><Citation>Hoshino A, Toyofuku E, Mitsuiki N, et al. Clinical courses of IKAROS and CTLA4 deficiencies: a systematic literature review and retrospective longitudinal study. Front Immunol. 2022;12:784901.</Citation></Reference><Reference><Citation>Jamee M, Hosseinzadeh S, Sharifinejad N, et al. Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review. Clin Exp Immunol. 2021;205(1):28-43.</Citation></Reference><Reference><Citation>Haute Autorit&#xe9; de sant&#xe9;. Protocole national de diagnostic et de soins. Purpura thrombop&#xe9;nique immunologique de l'enfant et de l'adulte. 2022 https://www.has-sante.fr/upload/docs/application/pdf/2017-06/dir36/pnds-_purpura_thrombopenique_immunologique.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>